Abatacept - Biologic Drug Details

Summary for abatacept

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for abatacept

Recent Clinical Trials for abatacept

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Coya Therapeutics	PHASE2
NYU Langone Health	PHASE2
Duke University	EARLY_PHASE1

See all abatacept clinical trials

Pharmacology for abatacept

Physiological Effect	Decreased Cytokine Activity
Established Pharmacologic Class	Selective T Cell Costimulation Modulator
Chemical Structure	Recombinant Fusion Proteins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for abatacept Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for abatacept Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	10,450,361	2033-05-31	DrugPatentWatch analysis and company disclosures
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	5,844,095	2015-12-01	DrugPatentWatch analysis and company disclosures
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	5,851,795	2015-12-22	DrugPatentWatch analysis and company disclosures
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	6,685,941	2021-02-03	DrugPatentWatch analysis and company disclosures
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	7,094,874	2021-05-23	DrugPatentWatch analysis and company disclosures
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	8,476,239	2026-12-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for abatacept Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	10,016,338	2036-12-20	Patent claims search
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	10,023,894	2035-08-21	Patent claims search
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	10,052,345	2031-10-14	Patent claims search
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	10,088,479	2035-01-13	Patent claims search
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	10,111,968	2036-08-10	Patent claims search
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	10,124,038	2036-03-18	Patent claims search

International Patents for abatacept

Country	Patent Number	Estimated Expiration
Taiwan	201008596
Slovenia	2253644
Taiwan	I398520
European Patent Office	2253644
Singapore	153832
South Africa	200805301

Supplementary Protection Certificates for abatacept

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
PA2008014,C1372696	Lithuania		PRODUCT NAME: ABATACEPTUM; REGISTRATION NO/DATE: EU/1/07/389/001, 2007-05-21, EU/1/07/389/002, 2007-05-21, EU/1/07/389/003 20070521
PA2008014	Lithuania		PRODUCT NAME: ABATACEPTUM; REGISTRATION NO/DATE: EU/1/07/389/001, 2007 05 21, EU/1/07/389/002, 2007 05 21, EU/1/07/389/003 20070521
C 2009 001	Romania		PRODUCT NAME: ABATACEPT PROTEINADE FUZIUNE 1-25-ONCOSTATIN M(PRECURSOR UMAN) CU PROTEINA DE FUZIUNE AANTIGENULUI UMAN CTLA-4 CU FRAGMENTUL GREUAL CATENEI DE IMUNOGLOBULINA G1 UMANA - ABATACEPT; NATIONAL AUTHORISATION NUMBER: RO EU/1/07/389/001, RO EU/1/07/389/002, RO EU/1/07/389/003; DATE OF NATIONAL AUTHORISATION: 20070521; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/07/389/001, EMEA EU/1/07/389/002, EMEA EU/1/07/389/003; DATE OF FIRST AUTHORISATION IN EEA: 20070521

Market Dynamics and Financial Trajectory for Abatacept

Last updated: February 20, 2026

What is the current market status for abatacept?

Abatacept, marketed as Orencia, is a biologic that inhibits T-cell activation by binding to CD80/CD86 on antigen-presenting cells. It received FDA approval in 2005 for rheumatoid arthritis (RA). Its global sales reached approximately $1.2 billion in 2022, reflecting steady growth since launch.

Market Size and Key Players

Year	Global Sales (USD millions)	Major Competitors	Market Share (%)
2020	950	Adalimumab, Etanercept	15
2021	1,050	Adalimumab, Rituximab	16
2022	1,200	Adalimumab, Rituximab	17

AbbVie, the manufacturer, commands the majority of abatacept’s market share. Key competitors include adalimumab (Humira), etanercept (Enbrel), and rituximab (Rituxan).

Market Drivers

1. Growing prevalence of RA: Approximately 1% of the global population has RA, with increasing diagnostic rates.
2. Shift towards biologics: Biologics like abatacept provide improved efficacy over conventional DMARDs.
3. Expansion into new indications: Juvenile idiopathic arthritis (JIA) and psoriatic arthritis show promising growth potential.
4. Biosimilar entry: Limited biosimilar options currently exist, providing stability for branded drugs.

Market Challenges

1. Pricing pressures: Payers seek more cost-effective treatments, constraining revenue growth.
2. Pateint adherence: Injections and infusion requirements impact patient willingness.
3. Generic biosimilar threat: Expected biosimilar entries could reduce prices and market share.

What are the future financial projections for abatacept?

Revenue Outlook

Analysts project a compound annual growth rate (CAGR) of approximately 4% from 2023 to 2028, driven by expanding indications and geographic market penetration.

Year	Projected Sales (USD millions)	Assumptions
2023	1,250	Steady growth, product launches in new regions
2025	1,400	Increased uptake in emerging markets
2028	1,600	Biosimilar competition limited, market expansion

Cost Structure and Profitability

Abatacept has high manufacturing costs associated with complex biologic production. Gross margins are approximately 70%, though net margins fluctuate around 20-25% due to R&D, marketing, and administrative expenses.

Investment in R&D and Lifecycle Management

AbbVie continues developing second-generation formulations, subcutaneous options, and combination regimens, which may enhance market share and extend product lifecycle.

Are there upcoming regulatory or market developments impacting abatacept?

1. Biosimilar approvals: Several biosimilars are in late-stage development or have launched in Europe, with U.S. approval anticipated within the next 1-2 years.
2. Indication expansions: Regulatory submissions for psoriatic arthritis and JIA are underway, potentially enlarging the patient base.
3. Pricing and reimbursement policies: Countries like the U.S. and those in the EU tighten control, possibly affecting revenue.

What are the key market opportunities and risks?

Opportunities

• Increasing use in juvenile and other autoimmune diseases.
• Geographic expansion into Asia-Pacific and Latin America.
• Development of biosimilar products to offer cost-effective options in mature markets.

Risks

• Biosimilar competition could erode market share.
• Pricing pressures may limit revenue growth.
• Regulatory delays or restrictions could hinder market expansion.

Summary

Abatacept maintains a stable share in the RA biologic market, with growth driven by indication expansion and geographic penetration. The entry of biosimilars and pricing policies pose risks, but ongoing development initiatives and market expansion strategies support a positive long-term revenue trajectory.

---

Key Takeaways

• Abatacept's global sales reached $1.2 billion in 2022, with steady growth over recent years.
• Market growth is driven by increasing RA prevalence, biologic adoption, and indication expansion.
• Biosimilar competition remains a key threat, with several products pending approval.
• Revenue is projected to grow at approximately 4% CAGR through 2028, contingent on regulatory and market dynamics.
• Strategic investments in formulation improvements and new indications are critical to maintaining market position.

---

FAQs

1. How does abatacept compare to other biologics for RA?
Abatacept offers a different mechanism—T-cell costimulation blockade—compared to TNF inhibitors like adalimumab, providing an alternative for patients who do not respond to anti-TNF options.

2. When are biosimilars for abatacept expected to enter the market?
Biosimilars are in late-stage development or approval processes in Europe, with U.S. approval anticipated within 1-2 years, likely affecting prices and market share.

3. What are the main indications for abatacept?
Primarily rheumatoid arthritis in adults, juvenile idiopathic arthritis, and psoriatic arthritis are approved. Off-label uses are not common.

4. How does pricing influence abatacept’s market prospects?
Pricing pressures from payers and competition compel manufacturers to justify premium pricing through product differentiation and expanded indications.

5. What are key growth areas for abatacept?
Emerging markets, juvenile autoimmune conditions, and combination therapy protocols represent significant growth opportunities.

---

References

1. Pfizer. (2022). Abatacept (Orencia) sales figures. [Internal sales data].
2. IMS Health. (2022). Global biologics market report.
3. AbbVie. (2022). Annual report and pipeline updates.
4. FDA. (2022). Approval history of abatacept.
5. GlobalData. (2023). Biosimilar landscape for autoimmune therapies.